Found 13 articles for: "JAK Inhibitor"
Efficacy, Safety, and Real-World Aspects of Janus Kinase Inhibitors to Treat Patients With Alopecia Areata
March 2026 | Volume 25 | Issue 3 | Original Article | 204 | Copyright © March 2026
Alopecia areata (AA) is an autoimmune disease characterized by nonscarring hair loss on the scalp and body, leading to a reduced quality of life and psychosocial burden for patients. The only US ...
Read MoreError: 429: HTTP/2 429Expert Consensus on Advanced Topical Nonsteroidal Therapies for Chronic Hand Eczema
March 2026 | Volume 25 | Issue 3 | | 228 | Copyright © March 2026
Background: Chronic hand eczema (CHE) is a common, heterogeneous inflammatory skin disease associated with substantial symptom burden, impaired hand function, reduced quality of ...
Read MoreBaricitinib-Related Adverse Events in Alopecia Areata and Rheumatoid Arthritis: A Comparative Study
March 2026 | Volume 25 | Issue 3 | Features | 286 | Copyright © March 2026
Treatment of Generalized Granuloma Annulare With Biologics and Oral JAK Inhibitors: A Case Series
February 2026 | Volume 25 | Issue 2 | Features | e26 | Copyright © February 2026
Treatment of Refractory Pruritic Dermatitis in the Setting of Primary Biliary Cholangitis and CREST Syndrome With Upadacitinib
November 2025 | Volume 24 | Issue 11 | | 1138 | Copyright © November 2025
Primary biliary cholangitis (PBC) can present with overlapping features of limited systemic sclerosis, commonly known as calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, a...
Read MoreManagement of Hailey-Hailey Disease With Ruxolitinib 1.5% Cream
November 2025 | Volume 24 | Issue 11 | Case Reports | 1141 | Copyright © November 2025
Introduction: Benign Familial Pemphigus (Hailey-Hailey Disease [HHD]) is a rare chronic condition, with treatments focusing on managing disease symptoms.Case...
Read MoreError: 429: HTTP/2 429Ruxolitinib Cream Versus Triamcinolone Cream in Adults With Mild to Moderate Atopic Dermatitis
October 2025 | Volume 24 | Issue 10 | | 1036 | Copyright © October 2025
Atopic dermatitis (AD), a chronic inflammatory skin disease, is typically treated with topical corticosteroids in patients with mild to moderate disease, creating an ongoing need for nonsteroidal...
Read MoreError: 429: HTTP/2 429The Role of Simultaneous Janus Kinase Inhibitor and Biologic Therapy Use for Refractory Atopic Dermatitis
October 2025 | Volume 24 | Issue 10 | | 1043 | Copyright © October 2025
Alopecia Universalis: Never Give Up?
March 2025 | Volume 24 | Issue 3 | Case Reports | 316 | Copyright © March 2025
Introduction: Oral Janus kinase inhibitors (JAKi) have demonstrated significant promise in hair regrowth for severe alopecia areata. Baricitinib and ritlecitinib are two medicati...
Read MoreError: 429: HTTP/2 429The Role of JAK Inhibitors in the Treatment of Cutaneous Lupus Erythematosus: A Review
December 2024 | Volume 23 | Issue 12 | | 1100 | Copyright © December 2024
Cutaneous lupus erythematosus (CLE), a manifestation of the chronic autoimmune disease lupus erythematosus (LE), showcases diverse clinical, immunologic, and histologic attributes. CLE can be fur...
Read MoreError: 429: HTTP/2 429The ABCs of JAKis: A Clinician's Guide to Safety and Monitoring of the Systemic JAK Inhibitors
October 2024 | Volume 23 | Issue 10 | | 852 | Copyright © October 2024
Janus kinase inhibitors (JAKis) have recently emerged in the arsenal of tools to treat dermatological conditions. However, there are some concerns regarding these treatments due to their boxed wa...
Read MoreAnalysis of Reddit Reveals JAK Inhibitor Questions Among Atopic Dermatitis Patients
April 2024 | Volume 23 | Issue 4 | Editorials | e121 | Copyright © April 2024
Reddit is a popular social media website that is increasingly being used as a source of health information and discussion, especially among the younger population. We analyzed the subreddit "ecze...
Read MoreError: 429: HTTP/2 429JAK Inhibitor Safety Compared to Traditional Systemic Immunosuppressive Therapies
December 2022 | Volume 21 | Issue 12 | | 1298 | Copyright © December 2022
Dermatologists treating atopic dermatitis are interested in the safety profile of the recently available JAK inhibitors, upadacitinib and abrocitinib, especially after they received boxed safety warni...
Read More© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
